Priya Marreddy
Hoofd Techniek/Wetenschap/O&O bij CONTEXT THERAPEUTICS INC.
Actieve functies van Priya Marreddy
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CONTEXT THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2022 | - |
Loopbaan van Priya Marreddy
Eerdere bekende functies van Priya Marreddy
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Priya Marreddy
| George Washington University | Undergraduate Degree |
| University of Pennsylvania | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CONTEXT THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
- Beurs
- Insiders
- Priya Marreddy
- Ervaring
